J&J’s oral dengue drug shows promise in human challenge study

2023-10-20

临床2期临床结果siRNAAACR会议

Johnson & Johnson’s Janssen Pharmaceutical unit announced Friday that the experimental oral drug JNJ-1802 induced antiviral activity against dengue in a Phase IIa study and was safe and well tolerated. The company noted that JNJ-1802 is the first antiviral to show such activity in humans during a clinical trial.

The human challenge study evaluated the antiviral activity of three dosing regimens of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults. All participants received daily doses of JNJ-1802 or placebo over 26 days, during which they were challenged with DENV-3 on day five.

According to Janssen, JNJ-1802 induced prophylactic antiviral activity against dengue, with a dose-dependent effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo. The results were presented at the American Society of Tropical Medicine & Hygiene (ASTMH) annual meeting.

JNJ-1802 is now being investigated in a community-based field study to establish efficacy against circulating dengue serotypes in a real-world setting. The trial sites are in countries including Philippines, Thailand, Peru, Brazil and Colombia.

More to come.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构